$TNXP

$5.39 +$0.09 (1.7%) Close

$TNXP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$TNXP Management Team

Dr. Seth Lederman

Chairman of the Board

President

Chief Executive Officer

Age 67

Compensation $1.810M USD

Sex Male

Mr. Bradley Saenger

Chief Financial Officer

Treasurer

Age 51

Compensation $850.0K USD

Sex Male

Ms. Jessica Morris

Chief Operating Officer

Age 46

Compensation $887.7K USD

Sex Female

Dr. Gregory Sullivan

Chief Medical Officer

Secretary

Age 59

Compensation $922.4K USD

Sex Male

Ms. Siobhan Fogarty

Chief Technical Officer

Age 56

Compensation -

Sex Female

Ms. Irina Ishak

General Counsel

Age -

Compensation -

Sex Female

Name / Title	Age	Compensation	Sex
Dr. Seth Lederman Chairman of the Board President Chief Executive Officer	67	$1.810M USD	Male
Mr. Bradley Saenger Chief Financial Officer Treasurer	51	$850.0K USD	Male
Ms. Jessica Morris Chief Operating Officer	46	$887.7K USD	Female
Dr. Gregory Sullivan Chief Medical Officer Secretary	59	$922.4K USD	Male
Ms. Siobhan Fogarty Chief Technical Officer	56	-	Female
Ms. Irina Ishak General Counsel	-	-	Female

Board of Directors

From the proxy statement filed Mar 30, 2026

Directors

serving now

Independent

7 of 9

stated in the proxy

Average tenure

5.9 years

from year joined

CEO also chairs the board

Yes

Seth Lederman

Director	Age	On board	Independent	Committees	Other public boards	Pay
Seth Lederman Board chair, CEO	68	Not stated	Not independent	None stated	None stated	Paid as CEO
Richard Bagger	66	2020 6 years	Independent	None stated	None stated	Not stated
Margaret Smith Bell	66	2017 9 years	Independent	None stated	None stated	Not stated
David Grange	78	2018 8 years	Independent	None stated	None stated	Not stated
James Hunter	70	2025 1 year	Not independent	None stated	None stated	Not stated
Newcomb Stillwell	69	2023 3 years	Independent	None stated	None stated	Not stated
Adeoye Olukotun	81	2018 8 years	Independent	None stated	Arrowhead Pharmaceuticals	Not stated
Carolyn Taylor	66	2021 5 years	Independent	None stated	None stated	Not stated
James Treco Lead independent director	70	2019 7 years	Independent	None stated	None stated	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Mar 30, 2026

Point72 Asset Management, L.P.

holder of 5% or more of our common stock

Offering price per share of common stock was $16.26

December 2025

Sale of 615,025 shares of common stock and pre-funded warrants to purchase up to 615,025 shares in a registered direct offering to an affiliate of Point72 Asset Management, L.P.

With Point72 Asset Management, L.P. Open in proxy

Comments

Company Executives

$TNXP Management Team

Dr. Seth Lederman

Mr. Bradley Saenger

Ms. Jessica Morris

Dr. Gregory Sullivan

Ms. Siobhan Fogarty

Ms. Irina Ishak

Board of Directors

Related-party transactions